Teva Pharmaceutical Industries Limited or Bio-Techne Corporation: Who Invests More in Innovation?

Teva vs. Bio-Techne: A Decade of R&D Investment

__timestampBio-Techne CorporationTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014309450001488000000
Thursday, January 1, 2015408530001525000000
Friday, January 1, 2016451870002111000000
Sunday, January 1, 2017535140001848000000
Monday, January 1, 2018553290001213000000
Tuesday, January 1, 2019624130001010000000
Wednesday, January 1, 202065192000997000000
Friday, January 1, 202170603000967000000
Saturday, January 1, 202287140000838000000
Sunday, January 1, 202392493000953000000
Monday, January 1, 202496664000998000000
Loading chart...

Unleashing the power of data

Innovation Investment: A Tale of Two Giants

In the competitive world of pharmaceuticals and biotechnology, innovation is the key to staying ahead. Teva Pharmaceutical Industries Limited and Bio-Techne Corporation are two industry leaders, each with a unique approach to research and development (R&D) investment. Over the past decade, Teva has consistently outspent Bio-Techne, with R&D expenses peaking at nearly 2.1 billion USD in 2016. In contrast, Bio-Techne's investment has shown a steady upward trend, growing by approximately 212% from 2014 to 2023. While Teva's spending has fluctuated, Bio-Techne's commitment to innovation has been unwavering, with a notable increase of 50% from 2019 to 2023. This data highlights the strategic differences in how these companies prioritize innovation, with Teva focusing on large-scale investments and Bio-Techne emphasizing consistent growth. As the industry evolves, these investment strategies will play a crucial role in shaping their future success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025